The choice of targeted therapy for patients with metastatic breast cancer is guided by ER, PR, and HER2 status of the primary tumor, despite evidence indicating that hormone receptor status may change during tumor progression [4, 6, 11]. The gene discussed is ESR1; the disease is neoplasm.